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Induced pluripotent stem cells (iPSCs) hold great promise in all the fields of regenerative medicine. In this review, a retrospective of
the progress in the potential treatment for diabetes mellitus is offered. The challenges this technology encounters are also assayed
and future directions examined in order to bypass these issues.
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INTRODUCTION
The progress made during the end of the last century in reprogramming
by nuclear transfer and fusion lead to Takahashi and Yamanaka to
hypothesize that there should be certain factors that determine the
differentiation fate of cells. Thus iPSCs were created in 2006 and a new
scientific stream started developing. Despite their origin, iPSCs are very
similar to embryonic stem cells (ESCs), avoiding most of the issues
related to the latter, and may be even able to replace them in a future.
This technology is in its early days, but lots of possible applications have
already been found. One of them is the production of β-like cells in
order to treat and study diabetes mellitus (DM).
FIRST REPORTS AND MOVING FORWARD
Soon after the discovery of iPS cells, a series of
reports suggested that developing insulin producing
β-like cells from iPSCs was feasible. One of the most
remarkable reports was in 2010 when Alipio’s group
was able to stably engraft these cells into the liver
of 30 T2DM and 6 T1DM mice and normalize their
blood glucose levels for more than 3 months2. Jeon
was able to repeat the experiment with very similar
results on T1DM mice3 (Figure 3).
Since then, a vast amount of research has been
done in order to improve the technology and
bypass its main issues. A combination of small
molecules like DNA methyl transferase inhibitor 5-
aza-2’-deoxycytidine (5-AZA) can guide the cellular
reprogramming and even the generation of β cells,
thus avoiding immunogenicity4.
Another important breakthrough was made by 
Pagliuca’s group (Figure 2) with the discovery of a 
strategy for large-scale production of functional β-
cells allowing the cultivation of 300 million cells per 
single 500 ml flask5.
CONCLUSIONS
iPSC technology offers a promising solution for the understanding and
treatment of DM and it has become a pillar of regenerative medicine. The
main challenges have been clearly defined which allows for better approach
strategies and more structured research.
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Figure 4. Problems of
generating iPSCs as the
source for pancreatic-
like β-cells6
β-CELL GENERATION AND MATURATION
Through functional genomics the role of some transcription factors
have been identified. These have been used to differentiate hESCS
and iPSCs into β-like cells (Figure 1), although we still need a wider
understanding to develop fully mature β-cells.
Figure 3. Blood glucose levels in transplanted STZ-
induced diabetic mice3
CHALLENGES AND FUTURE DIRECTIONS
Nevertheless, the technology is not prepared for clinical trials and many issues have
to be taken care of first (Figure 4 and Table 1):
Figure 2. Reprogramming steps from iPSCs to β-cells








Table 1. Proposed future directions in order to bypass the current challenges in diabetes treatment with iPSCs.
